Nkarta (NASDAQ: NKTX) said it expects to present initial clinical data from its autoimmune disease p

Nkarta NASDAQ: NKTX said it expects to present initial clinical data from its autoimmune disease pro

Nkarta, Inc. (NASDAQ: NKTX - Get Free Report)'s stock price fell 3.5% during trading on Friday. The

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clini

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clini

BlackRock Inc. bought a new stake in Nkarta, Inc. (NASDAQ: NKTX) in the second quarter, according to

Stifel analyst Stephen Willey maintains Nkarta (NASDAQ:NKTX) with a Buy and lowers the price targ

HC Wainwright & Co. analyst Emily Bodnar maintains Nkarta (NASDAQ:NKTX) with a Buy and lowers

Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.54) per share which missed the analyst consens

Paris, France and New York, USA , July 23, 2026 (GLOBE NEWSWIRE) -- Paris, France and New York, USA,

At 2 p.m. ET on Tuesday, June 30th, Nkarta President Nadir Mahmood will take part in a fireside at t

/PRNewswire/ -- USA News Group Market Commentary - Start with the number that makes everyone do a do

Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.37) per share which met the analyst consensus

Enrollment ongoing at 4 billion cell dose level (12 billion cells in 3-dose cycle) across all indica

Nkarta stock jumps after FDA backs protocol changes for ongoing NKX019 studies, enabling outpatient

SOUTH SAN FRANCISCO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clini

SOUTH SAN FRANCISCO, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clini

Nkarta, Inc. (NASDAQ: NKTX - Get Free Report) has earned a consensus rating of "Hold" from the five

Mizuho analyst Salim Syed maintains Nkarta (NASDAQ:NKTX) with a Outperform and lowers the price t

Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.37) per share which missed the analyst consens

SOUTH SAN FRANCISCO, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clini

Nkarta (NASDAQ: NKTX - Get Free Report) and Bolt Biotherapeutics (NASDAQ: BOLT - Get Free Report) ar

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinic

AWM Investment Company Inc. trimmed its position in shares of Nkarta, Inc. (NASDAQ: NKTX) by 30.0% d

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinic

Nkarta Inc. remains a compelling buy as it pivots its NK cell therapy pipeline toward autoimmune dis

Stifel analyst Stephen Willey maintains Nkarta (NASDAQ:NKTX) with a Buy and lowers the price targ

Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.29) per share which beat the analyst consensus

Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural

Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acqu

Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company report

Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCo

  On Monday, 369 companies set new 52-week lows.

  Friday's session saw 112 companies set new 52-week lows.

  On Thursday, 283 companies set new 52-week lows.

  On Thursday, 109 companies set new 52-week lows.

  On Wednesday, 220 stocks hit new 52-week lows.

  On Friday, 469 companies hit new 52-week lows.

  On Friday, 497 companies set new 52-week lows.

  On Friday, 135 companies reached new 52-week lows.

  OnWednesday, 78 stocks made new 52-week lows.

  Thursday's session saw 329 companies set new 52-week lows.

  During Friday's trading, 293 companies set new 52-week lows.

  On Thursday, 241 companies hit new 52-week lows.